These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. Gebauer K; Reinecke H Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075 [TBL] [Abstract][Full Text] [Related]
7. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061 [TBL] [Abstract][Full Text] [Related]
8. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events. Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of PCSK9 monoclonal antibodies. Iqbal Z; Dhage S; Mohamad JB; Abdel-Razik A; Donn R; Malik R; Ho JH; Liu Y; Adam S; Isa B; Stefanutti C; Soran H Expert Opin Drug Saf; 2019 Dec; 18(12):1191-1201. PubMed ID: 31623472 [No Abstract] [Full Text] [Related]
10. Real-world use of PCSK9 inhibitors: A single-center experience. Sarsam S; Berry A; Degheim G; Singh R; Zughaib M J Int Med Res; 2019 Jan; 47(1):265-270. PubMed ID: 30280628 [TBL] [Abstract][Full Text] [Related]
11. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492 [TBL] [Abstract][Full Text] [Related]
12. Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels. Ye Q; Svatikova A; Meeusen JW; Kludtke EL; Kopecky SL Am J Cardiol; 2020 Aug; 128():163-167. PubMed ID: 32650914 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia. Dijk W; Cariou B Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456 [TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Julius U; Tselmin S; Schatz U; Fischer S; Bornstein SR Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):45-50. PubMed ID: 30838555 [TBL] [Abstract][Full Text] [Related]
15. PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. Raal FJ; Chilton R; Ranjith N; Rambiritch V; Leisegang RF; Ebrahim IO; Tonder AV; Shunmoogam N; Bouharati C; Musa MG; Karamchand S; Naidoo P; Blom DJ Endocr Metab Immune Disord Drug Targets; 2020; 20(6):840-854. PubMed ID: 32053090 [TBL] [Abstract][Full Text] [Related]
16. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]